🚀 VC round data is live in beta, check it out!
Nektar Therapeutics Valuation Multiples
Discover revenue and EBITDA valuation multiples for Nektar Therapeutics and similar public comparables like Cheezheng Tibetan Medicine, Aurinia Pharmaceuticals, Harrow, Stoke Therapeutics and more.
Nektar Therapeutics Overview
About Nektar Therapeutics
Nektar Therapeutics is a clinical-stage, research-based drug discovery biopharmaceutical company focused on discovering and developing medicines in the field of immunotherapy. The company is focused on discovering and developing medicines in the field of immunotherapy. Its pipeline products are REZPEG (NKTR-358), REZPEG (NKTR-358), REZPEG (NKTR-358), NKTR-422, NKTR-0165, NKTR-255, and Others.
Founded
1990
HQ
Employees
61
Website
Sectors
Financials (LTM)
EV
$2B
Nektar Therapeutics Financials
Nektar Therapeutics reported last 12-month revenue of $52M and negative EBITDA of ($161M).
In the same LTM period, Nektar Therapeutics generated $52M in gross profit, ($161M) in EBITDA losses, and had net loss of ($182M).
Revenue (LTM)
Nektar Therapeutics P&L
In the most recent fiscal year, Nektar Therapeutics reported revenue of $55M and EBITDA of ($128M).
Nektar Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $52M | XXX | $55M | XXX | XXX | XXX |
| Gross Profit | $52M | XXX | $55M | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | 100% | XXX | XXX | XXX |
| EBITDA | ($161M) | XXX | ($128M) | XXX | XXX | XXX |
| EBITDA Margin | (308%) | XXX | (232%) | XXX | XXX | XXX |
| EBIT Margin | (303%) | XXX | (237%) | XXX | XXX | XXX |
| Net Profit | ($182M) | XXX | ($164M) | XXX | XXX | XXX |
| Net Margin | (348%) | XXX | (297%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Nektar Therapeutics Stock Performance
Nektar Therapeutics has current market cap of $2B, and enterprise value of $2B.
Market Cap Evolution
Nektar Therapeutics' stock price is $71.01.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2B | $2B | 0.0% | XXX | XXX | XXX | $-5.86 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialNektar Therapeutics Valuation Multiples
Nektar Therapeutics trades at 34.6x EV/Revenue multiple, and (11.2x) EV/EBITDA.
EV / Revenue (LTM)
Nektar Therapeutics Financial Valuation Multiples
As of March 18, 2026, Nektar Therapeutics has market cap of $2B and EV of $2B.
Equity research analysts estimate Nektar Therapeutics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Nektar Therapeutics has a P/E ratio of (10.9x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2B | XXX | $2B | XXX | XXX | XXX |
| EV (current) | $2B | XXX | $2B | XXX | XXX | XXX |
| EV/Revenue | 34.6x | XXX | 32.7x | XXX | XXX | XXX |
| EV/EBITDA | (11.2x) | XXX | (14.1x) | XXX | XXX | XXX |
| EV/EBIT | (11.4x) | XXX | (13.8x) | XXX | XXX | XXX |
| EV/Gross Profit | 34.6x | XXX | 32.7x | XXX | XXX | XXX |
| P/E | (10.9x) | XXX | (12.1x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (8.7x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Nektar Therapeutics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Nektar Therapeutics Margins & Growth Rates
Nektar Therapeutics' revenue in the last 12 month declined by (24%).
Nektar Therapeutics' revenue per employee in the last FY averaged $0.9M.
Nektar Therapeutics' rule of 40 is (332%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Nektar Therapeutics' rule of X is (367%) (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Nektar Therapeutics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | (24%) | XXX | (25%) | XXX | XXX | XXX |
| EBITDA Margin | (308%) | XXX | (232%) | XXX | XXX | XXX |
| EBITDA Growth | 69% | XXX | 90% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | (332%) | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | (367%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.9M | XXX | XXX | XXX |
| G&A Expenses to Revenue | 136% | XXX | 124% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 263% | XXX | 212% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 337% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Nektar Therapeutics Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Cheezheng Tibetan Medicine | XXX | XXX | XXX | XXX | XXX | XXX |
| Aurinia Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Harrow | XXX | XXX | XXX | XXX | XXX | XXX |
| Stoke Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Celldex Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Nektar Therapeutics M&A Activity
Nektar Therapeutics acquired XXX companies to date.
Last acquisition by Nektar Therapeutics was on XXXXXXXX, XXXXX. Nektar Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Nektar Therapeutics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialNektar Therapeutics Investment Activity
Nektar Therapeutics invested in XXX companies to date.
Nektar Therapeutics made its latest investment on XXXXXXXX, XXXXX. Nektar Therapeutics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Nektar Therapeutics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Nektar Therapeutics
| When was Nektar Therapeutics founded? | Nektar Therapeutics was founded in 1990. |
| Where is Nektar Therapeutics headquartered? | Nektar Therapeutics is headquartered in United States. |
| How many employees does Nektar Therapeutics have? | As of today, Nektar Therapeutics has over 61 employees. |
| Who is the CEO of Nektar Therapeutics? | Nektar Therapeutics' CEO is Howard W. Robin. |
| Is Nektar Therapeutics publicly listed? | Yes, Nektar Therapeutics is a public company listed on Nasdaq. |
| What is the stock symbol of Nektar Therapeutics? | Nektar Therapeutics trades under NKTR ticker. |
| When did Nektar Therapeutics go public? | Nektar Therapeutics went public in 1994. |
| Who are competitors of Nektar Therapeutics? | Nektar Therapeutics main competitors are Cheezheng Tibetan Medicine, Aurinia Pharmaceuticals, Harrow, Stoke Therapeutics. |
| What is the current market cap of Nektar Therapeutics? | Nektar Therapeutics' current market cap is $2B. |
| What is the current revenue of Nektar Therapeutics? | Nektar Therapeutics' last 12 months revenue is $52M. |
| What is the current revenue growth of Nektar Therapeutics? | Nektar Therapeutics revenue growth (NTM/LTM) is (24%). |
| What is the current EV/Revenue multiple of Nektar Therapeutics? | Current revenue multiple of Nektar Therapeutics is 34.6x. |
| Is Nektar Therapeutics profitable? | No, Nektar Therapeutics is not profitable. |
| What is the current EBITDA of Nektar Therapeutics? | Nektar Therapeutics has negative EBITDA and is not profitable. |
| What is Nektar Therapeutics' EBITDA margin? | Nektar Therapeutics' last 12 months EBITDA margin is (308%). |
| What is the current EV/EBITDA multiple of Nektar Therapeutics? | Current EBITDA multiple of Nektar Therapeutics is (11.2x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.